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Increased levels of 30-50-cyclic adenosine monophosphate
(cAMP) stimulate cell proliferation and fluid secretion in
polycystic kidney disease. Levels of this molecule are more
sensitive to inhibition of phosphodiesterases (PDEs), whose
activity far exceeds the rate of cAMP synthesis by adenylyl
cyclase. Several PDEs exist, and here we measured the
activity and expression of PDE families, their isoforms, and
the expression of downstream effectors of cAMP signaling in
the kidneys of rodents with polycystic kidney disease. We
found a higher overall PDE activity in kidneys from mice as
compared with rats, as well as a higher contribution of PDE1,
relative to PDE4 and PDE3, to total PDE activity of kidney
lysates and lower PDE1, PDE3, and PDE4 activities in the
kidneys of cystic as compared with wild-type mice. There
were reduced amounts of several PDE1, PDE3, and PDE4
proteins, possibly due to increased protein degradation
despite an upregulation of their mRNA. Increased levels of
cGMP were found in the kidneys of cystic animals, suggesting
in vivo downregulation of PDE1 activity. We found an
additive stimulatory effect of cAMP and cGMP on
cystogenesis in vitro. Cyclic AMP–dependent protein kinase
subunits Ia and IIb, PKare, the transcription factor CREB-1
mRNA, and CREM, ATF-1, and ICER proteins were upregulated
in the kidneys of cystic as compared with wild-type animals.
Our study suggests that alterations in cyclic nucleotide
catabolism may render cystic epithelium particularly
susceptible to factors acting on Gs-coupled receptors. This
may account, in part, for increased cyclic nucleotide signaling
in polycystic kidney disease and contribute substantially to
disease progression.
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Autosomal dominant polycystic kidney disease (ADPKD)
and autosomal recessive polycystic kidney disease are
common inherited renal cystic diseases for which there is
no proven effective therapy.1–6 ADPKD is caused by
mutations in PKD1 encoding polycystin-1 (PC1) or PKD2
encoding polycystin-2. Autosomal recessive polycystic kidney
disease is caused by mutations in PKHD1 encoding
fibrocystin/polyductin. Both diseases show large inter- and
intra-familial variability, in part because of the effect of
modifier genes that remain largely unidentified.
Recent studies have established that 30-50-cyclic adenosine
monophosphate (cAMP) stimulates mural epithelial cell
proliferation and secretion of fluid into cysts of patients
with ADPKD.7–11 Increased levels of cAMP are found in the
kidney, liver, vascular smooth muscle, and choroid plexus, in
various animal models of PKD.12–19 Arginine vasopressin
(AVP) V2R antagonists lower the levels of cAMP in the
kidneys and inhibit the development and progression of PKD
in models orthologous to autosomal recessive polycystic
kidney disease (PCK rat), adolescent nephronophthisis (pcy
mouse), and ADPKD type 2 (Pkd2/WS25 mouse).13,14,20
Genetic elimination of AVP in PCK rats yields animals that
remain relative free of cysts, unless an exogenous V2R agonist
is administered.21 Octreotide also lowers the tissue levels of
cAMP and has a protective effect not only in the kidney, but
also in the liver.18 The ability to hormonally modulate cAMP
in a cell-specific manner minimizes adverse effects, obviously
important for the treatment of a chronic disease. Clinical trials
of AVP V2R antagonists (NCT00413777 and NCT00428948)
and long-acting somatostatin analogs (NCT00309283,
NCT00565097, and NCT00426153) are currently active.
The mechanisms responsible for the accumulation of
cAMP in cystic tissues and for its effect on cystogenesis are
not well understood. In view of the importance of PKD
proteins in the regulation of intracellular calcium and
calcium in the regulation of cAMP metabolism, changes in
intracellular calcium may be responsible for the accumulation
of cAMP in cystic tissues.13,14,22 As the hydrolytic capacity of
phosphodiesterases (PDEs) far exceeds the maximum rate of
synthesis by adenylyl cyclases, cellular levels of cAMP are
thought to be more sensitive to inhibition of PDEs than to
changes in the activity of adenylyl cyclases. Recently, a new class
of compounds, the 2-(acylamino)-3-thiophenecarboxylates,
has been shown to function as nonselective phosphodiesterase
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activators and inhibit the growth of Madin–Darby canine
kidney (MDCK) cysts.23
Limited information is available on the pattern of
expression of the different PDE isoforms and of the
downstream effectors that are thought to mediate the
cystogenic effect of cAMP in polycystic kidneys. Therefore,
we have used enzymatic, western blot, PCR, and biochemical
assays to study the expression of different PDE isoforms and
downstream effectors of cAMP signaling in wild-type and
polycystic rat and mouse kidneys.
RESULTS
PDE1, PDE3, and PDE4 enzymatic activity
Total PDE activity was significantly higher in kidney lysates
from mice than in those from rats (Figure 1a and b). PDE1,
PDE3, and PDE4 accounted for 79.6±1.4, 2.8±0.4, and
11.2±1.1% of total PDE activity in lysates from wild-type
mice and for 67.6±5.4, 4.5±2.2, and 12.4±3.0% of total
PDE activity in lysates from wild-type rats. PDE1, PDE3, and
PDE4 activities were significantly lower in murine cystic
compared with wild-type kidneys. However, PDE activities
were similar in rat cystic and wild-type kidneys. As PDE
activities were expressed per mg of protein, protein
concentrations per wet tissue were significantly lower in the
cystic than in wild-type kidneys (12.4±1.1 vs 17.1±2.7%
and 10.5±2.6 vs 17.0±4.6% for mice and rats, respectively),
and PDE immunoreactivity was confined to cells (see below),
the reduction of PDE activities in cystic tissues was likely
underestimated. Cystic kidneys were studied at relatively
early stages of the disease (10-week-old rats with relative cyst
volume of 36.9%, fibrosis volume of 1.2%, and plasma blood
urea nitrogen concentration of 19.0 mg/dl; 16-week-old mice
with relative cyst volume of 32.6%, fibrosis volume of 3.3%,
and plasma blood urea nitrogen concentration of 31.6 mg/
dl). Therefore, it is unlikely that the changes observed are
secondary to severe azotemia or tubular dropout.
PDE1, PDE3, and PDE4 protein expression
Figure 1c and d compares the protein expressions of the
PDE1, PDE3, and PDE4 isoforms in mouse and rat wild-type
and cystic kidneys. Consistent with lower enzymatic activities
in murine cystic tissues, the protein levels of several PDE1,
PDE3, and PDE4 isoforms were significantly reduced in
cystic compared with wild-type kidneys. This occurred
despite over-expression of the corresponding PDE mRNAs
(see below), possibly reflecting increased protein catabolism
as suggested in some models of PKD.24
The immunohistochemical localization of PDE1, PDE3,
and PDE4 isoforms is shown in Figures 2 and 3. In wild-type
animals, PDE1A, PDE1C, and PDE3A were expressed in all
tubular segments and in collecting ducts, and the highest
level of expression was in the distal convoluted tubules
(Figure 2). The pattern of expression in the cystic animals
was similar, but immunostaining in the cysts was weak or
absent. PDE3B was more restricted to the distal tubules and
associated with vesicular or granular structures. The
immunostaining patterns of PDE4A, PDE4B, and PDE4D
in the renal cortex were similar to those of PDE1A, PDE1C,
and PDE3A, but medullary tubules and collecting ducts
showed only weak immunoreactivity (Figure 3). Moderate
immunostaining was detected in the cysts.
PDE1, PDE3, and PDE4 mRNA expression
Figure 1e and f compares relative PDE1, PDE3, and PDE4
mRNA expressions in wild-type and polycystic mouse and rat
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Figure 1 |PDE1, PDE3, and PDE4 in cystic and wild-type
kidneys. (a) Phosphodiesterase 1, 3, and 4 (PDE1, PDE3, and
PDE4) activities in whole lysates from kidneys of 10-week-old male
polycystic kidney (PCK; n¼ 6) and wild-type (n¼ 6) rats. (b) PDE1,
PDE3, and PDE4 activities in whole lysates from kidneys of
16-week-old male Pkd2/WS25 (n¼ 6) and wild-type (n¼ 6) mice.
(c) Western blots of PDE1, PDE3, and PDE4 isoforms in the kidneys
of 10-week-old male PCK (n¼ 4) and wild-type (n¼ 4) rats.
(d) Western blots of PDE1, PDE3, and PDE4 isoforms in the kidneys
of 16-week-old male Pkd2/WS25 (n¼ 4) and wild-type (n¼ 4) mice.
(e) PDE1, PDE3, and PDE4 mRNA expression measured using
reverse transcriptase PCR (RT-PCR) in the kidneys of 10-week-old
male PCK (n¼ 6) and wild-type (n¼ 6) rats. (f) PDE1, PDE3, and
PDE4 mRNA expression measured using RT-PCR in the kidneys of
16-week-old male Pkd2/WS25 (n¼ 6) and wild-type (n¼ 6) mice.
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whole-kidney lysates. There were marked species-specific
differences. The predominant PDE1 mRNAs in the rat kidney
were PDE1a and PDE1c, whereas the predominant PDE1
mRNA expressed in the mouse kidney was PDE1b. This was
unexpected because previous studies had shown PDE1b
expression to be restricted to the brain and not to the
kidney.25,26 However, the Uniport human kidney EST library
(HS.530871-PDE1B) shows expression of nine transcripts per
million in kidney (compared with 94 in the brain). PDE4d
mRNA was expressed at a higher level in the rat kidney than
in mouse kidney, whereas the reverse was true for PDE4c
mRNA. Significant differences were detected between wild-
type and cystic kidneys. In the rat, PDE3b, PDE4b, and
PDE4d mRNAs were over-expressed in cystic compared with
wild-type kidneys. In the mouse, PDE1a, PDE1c, PDE3a,
PDE3b, PDE4a, PDE4b, and PDE4d mRNAs were over-
expressed in cystic compared with wild-type kidneys.
mRNA expression of other PDE isoforms
Supplementary Figure 1 compares relative expressions of the
remaining PDE isoforms in wild-type and cystic kidneys.
Of these, PDE2 is known to be localized to the glomeruli and
PDE5 predominantly to the vasculature. The specific location
of the other PDE isoforms in the kidney has not been
characterized. The expressions of PDE7A and B and those of
PDE8A and B mRNAs are significantly higher in cystic than
in wild-type mouse kidneys, whereas no difference between
cystic and wild-type kidneys was detected in rats. Both PDE7
and PDE8 are highly specific for cAMP and may have a role
in T-lymphocyte activation.27
Cyclic GMP levels in polycystic kidneys
The increased levels of cAMP in cystic tissues may be because
of alterations of intracellular calcium and reduced in vivo
activity of PDE1, the only PDE regulated by calcium and
Figure 2 | Immunolocalization of PDE1 and PDE3 isoforms in cystic and wild-type kidneys. Immunolocalization of phosphodiesterase
(PDE) 1A (a, e, i, m), PDE1C (b, f, j, n), PDE3A (c, g, k, o), and PDE3B (d, h, l, p) in wild-type rat (a–h,  200) and mouse (i–l,  400;
insert, original magnification  800) and in polycystic kidney (PCK) rat (m–p, original magnification  200) kidneys. The immunostaining
pattern in Pkd2WS25/ mouse (not shown) was similar to that of PCK rat kidneys.
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calmodulin. As PDE1 isoforms have an affinity for cyclic
guanosine monophosphate (cGMP), which is equal or higher
than that for cAMP, the levels of cGMP would also be
increased if this hypothesis was correct. Indeed, the levels of
cGMP were found to be markedly elevated in the kidneys of
male and female PCK rats and PKD2/WS25 mice compared
with those in wild-type animals (Figure 4a and b). The ratio
of cGMP to cAMP was significantly higher in the kidneys of
PCK rats than in those of wild-type rats. Cyclic GMP and
cAMP were increased to the same extent in PKD2/WS25 mice
compared with wild-type mice.
Effect of cGMP on cystogenesis in hydrated collagen gels
To determine whether the increase in renal cGMP levels may
contribute to cystogenesis directly or indirectly, we have
studied the effects of 8-Br-cAMP and 8-Br-cGMP on an
in vitro system of cystogenesis using a cell line that does not
express PC1 at a protein level, MDCKZeo, and its control
transfected with full-length human PKD1, MDCKPKD1Zeo
(Figure 5a).28 Whereas 8-Br-cAMP and to a lesser extent
8-Br-cGMP stimulated the growth of cysts derived from
MDCKZeo cells, they had the opposite effect on cysts derived
from MDCKPKD1Zeo (Figure 5b and c). 8-Br-cAMP and
8-Br-cGMP had an additive effect on the growth of
MDCKZeo cysts. These results suggest a direct effect of
cGMP on cyst growth.
Changes in renal cGMP parallel those in cAMP in response to
interventions targeting AVP and the V2R in vivo
AVP V2R antagonists markedly reduce the renal levels of
cAMP and inhibit the development of PKD in PCK rats and
Pkd2/WS25 mice.13,14,20 Genetic elimination of circulating
AVP achieved by PCK–Brattleboro crosses has a similar
protective effect in the PCK rat. On the other hand,
Figure 3 | Immunolocalization of PDE4 isoforms in cystic and wild-type kidneys. Immunolocalization of phosphodiesterase (PDE) 4A
(a, d, g, j), PDE4B (b, e, h, k), and PDE4D (c, f, i, l) in wild-type rat (a–c, original magnification  200) and mouse (d–i,  400) and in
polycystic kidney disease (PCK) rat (j–l, original magnification  200) kidneys. The immunostaining pattern in Pkd2WS25/ mouse (not
shown) was similar to that of PCK rat kidneys.
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administration of the V2R agonist 1-deamino-8-D-arginine
AVP (DDAVP) increases the renal levels of cAMP, rescues the
cystic phenotype in PCK–Brattleboro rats, and aggravates the
cystic disease in PCK rats.21 To determine whether the renal
cGMP levels change in parallel to those of cAMP under these
conditions, we measured the cGMP levels in the polycystic
kidneys of the animals used in these experiments. The
administration of V2R antagonists (Figure 4c) and the
elimination of circulating AVP (Figure 4d) significantly
reduced the renal levels of cGMP, whereas the administration
of DDAVP had the opposite effect (Figure 4e). Although the
cGMP levels were lower than those of cAMP, the direction
and relative magnitude of the changes were similar.
Upregulation of PKA regulatory subunits in polycystic
kidneys
The proliferative response of the cystic epithelium to cAMP
in the kidney is mediated by cAMP-dependent protein kinase
(PKA), as it can be completely abrogated by a PKA inhibitor.
To examine whether alterations in PKA accompany the
development of PKD, we studied the renal expression of PKA
regulatory (R) and catalytic (C) subunits in wild-type and
polycystic kidneys. RIa and RIIb mRNAs were significantly
upregulated in the PCK rats and Pkd2/WS25 mice compared
with wild-type animals (Figure 6a and b). At the protein
level, RIIb was upregulated in the cystic kidneys of both rats
and mice, whereas RIa was markedly upregulated in mouse,
but not ostensibly in rat cystic kidneys (Figure 6c and d).
Strong RIa and RIIa immunoreactivities were observed in all
tubular segments (particularly in distal convoluted tubules)
and collecting ducts (Figure 7). Contrary to the reduced
expression of PDE1A, PDE1C, and PDE3A, RIa and RIIa
were strongly expressed in cysts, RIIb immunoreactivity was
restricted to stromal structures and vasa recta, and to tubular
epithelial cells in the outer medulla, and seemed to be more
prominent in cystic than in wild-type animals. PKare mRNA
was significantly upregulated in the cystic kidneys of both
rats and mice, whereas Ca and Cb subunits tended to be
increased at the mRNA but not at the protein level.
Upregulation of CREM and ICER in polycystic kidneys
The effects of cAMP on cell proliferation are likely mediated,
at least in part, by PKA-mediated phosphorylation of
transcription factors that bind to cAMP-responsive promoter
elements (CREs). We examined the expression of CRE-
binding protein (CREB) and CRE modulator proteins
(CREMs) in wild-type and polycystic kidneys. CREB-1
mRNA was significantly increased in the cystic tissues
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Figure 4 |Cyclic nucleotide levels in cystic and wild-type kidneys. (a) Cyclic guanosine monophosphate (cGMP) and cyclic adenosine
monophosphate (cAMP) levels and cGMP/cAMP ratios in the kidneys of polycystic kidney (PCK; male, n¼ 11; female, n¼ 11) and wild-type
(male, n¼ 11; female, n¼ 12) rats. (b) cGMP and cAMP levels and cGMP/cAMP ratios in the kidneys of Pkd2/WS25 (male, n¼ 10; female,
n¼ 10) and wild-type (male, n¼ 10; female, n¼ 10) mice. (c) cGMP levels in the kidneys of male PCK (n¼ 10) and male and female
Pkd2/WS25 (n¼ 10) mice and OPC-31260-treated male PCK (n¼ 7) and male and female Pkd2/WS25 (n¼ 11) mice. (d) cGMP levels in the
kidneys of wild-type (male, n¼ 10; female, n¼ 10), PCK (male, n¼ 10; female, n¼ 10), and PCK/Brattleboro rats (male¼ 10; female¼ 10).
(e) cGMP levels in the kidneys of PCK/Brattleboro rats (male, n¼ 4; female, n¼ 4) and their response to the administration of the V2
receptor agonist DDAVP (male, n¼ 4; female, n¼ 4).
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whereas no consistent difference was detected in the renal
level of expression of CREM-1 and inducible cAMP early
repressor (ICER) mRNAs between wild-type and cystic rats
or mice (Figure 8a and b). At the protein level, no consistent
differences were detected in the levels of CREB or P-CREB
between cystic and wild-type kidneys, whereas CREM-1,
activating transcription factor-1 (ATF-1), and ICER were
significantly increased in the nuclear extracts of cystic
compared with wild-type animals (Figure 8c and d). The
increased protein expression, without a change in mRNA
expression, is consistent with protein stabilization associated
with PKA activation, as it has been shown for ICER in cardiac
myocytes.29
DISCUSSION
The main observations of this study include the following.
(1) Species-specific differences in the expression of cyclic
nucleotide PDEs; higher PDE activity in whole-kidney lysates
from mice compared with those from rats; and higher
contribution of PDE1, relative to PDE4 and PDE3, to total
PDE activity of whole-kidney lysate, and lower PDE1, PDE3,
and PDE4 activities in murine cystic compared with wild-
type kidneys. (2) Reduced levels of several PDE1, PDE3, and
PDE4 protein isoforms despite upregulation at mRNA level,
possibly because of increased protein catabolism. (3)
Increased cGMP levels in polycystic kidneys, suggesting
functional in vivo downregulation of phosphodiesterase
PDE1, the only calcium-dependent PDE that is active against
cGMP and cAMP. (4) Additive stimulatory effect of cAMP
and cGMP on cystogenesis in vitro. (5) Upregulation of PKA
subunits Ia and IIb, PKA catalytic subunit PKare, CREB-1
mRNA, and CREM, ATF-1, and ICER proteins in cystic
compared with wild-type kidneys.
The superfamily of mammalian PDEs consists of 11
families (PDE1–PDE11) with 21 genes and more than 50
isoenzymes.27,30–32 PDE family members hydrolyze exclu-
sively cAMP (PDE4, PDE7, and PDE8), exclusively cGMP
(PDE5, PDE6, and PDE9), or both (PDE1, PDE2, PDE3,
PDE10, and PDE11). They are regulated at the genetic level,
as well as by phosphorylation, cGMP, or cAMP binding,
calmodulin binding, and protein–protein interactions.
Information on PDEs in renal tubules is limited.33–35
PDE1, PDE3, and PDE4 account for most of the cAMP PDE
activity, whereas PDE1 is responsible for most of the cGMP
PDE activity. In mixed cortical tubules and microdissected
tubular segments, 50–70% of cAMP PDE activity was found
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to be inhibitable by an inhibitor of the calcium–calmodulin-
sensitive PDE1 and PDE activity was higher in renal tubules
from mice than in those from rats and rabbits.36 Our results
are consistent with both observations. This, along with
species-specific differences noted in this study, raises the
possibility that variation in cyclic nucleotide metabolism
could result in variable susceptibility to renal cystic disease.
The PDE1 family consists of three members (PDE1A,
PDE1B, and PDE1C).37,38 They are the only PDEs activated
by calcium and integrate cyclic nucleotide and calcium
signaling pathways. Phosphorylation of PDE1A and PDE1C
by PKA and of PDE1B by calcium–calmodulin kinase II
reduces their affinity for calmodulin–calcium. PDE1 isoforms
are dephosphorylated and reactivated by calcium–calmodu-
lin-dependent protein phosphatase (calcineurin; protein
phosphatase 2B). Activation of Gs-coupled receptors
increases the concentration of cAMP (not only through
stimulation of adenylyl cyclase, but also through PKA-
mediated inhibition of PDE1 and possibly cGMP-mediated
inhibition of PDE3, see below) and evokes a physiological
response. A subsequent increase in intracellular calcium
through calcium influx activates calcineurin, overrides the
inhibition of PDE1 by PKA, and reduces intracellular cAMP
levels. A reduction in intracellular calcium in PKD would be
expected to result in increased cellular levels of cGMP
because of PDE1 inhibition and of cAMP as a result of
inhibition of PDE1 and cGMP-induced inhibition of PDE3
(see below). This may account for the increased levels of
cAMP and cGMP in polycystic kidneys. Interestingly,
administration of the calcineurin inhibitor cyclosporine has
been associated with acquired renal cystic disease after renal
transplantation and pediatric liver transplantation.39–41
The PDE3 family consists of two members (PDE3A and
PDE3B).29–31 PDE3 enzymes are mostly cAMP-specific PDEs,
are inhibited by cGMP, and mediate cross-talk between
cAMP and cGMP pathways. Thus, PDE3 inhibition by
increased cGMP levels may contribute to the accumulation of
cAMP in polycystic kidneys. In turn, increased accumulation
of cAMP may be responsible for the upregulation of PDE3
mRNA expression observed in this study.42
The PDE4 family consists of four subfamilies (PDE4A
through D) with approximately 20 isoforms.43 These have
tissue and cell type-specific expression. Their subcellular
targeting and physiological function are regulated by
A-kinase anchoring proteins.44 For example, PDE4d 3/9
isoforms interact with A-kinase anchoring protein 18 in
aquaporin-2-bearing vesicles and regulate PKA activity,
aquaporin-2 phosphorylation, and shuttling and water
permeability in the collecting duct principal cells.45,46 Despite
its importance in the regulation of urinary concentration, the
cAMP pool controlled by PDE4 does not seem to be
important in the regulation of tubular cell proliferation
(see below). Increased expression of certain PDE4 mRNAs in
cystic kidneys in this study is consistent with cAMP-driven
upregulation of PDE4 isoforms that are observed in other
tissues in other studies.47–49
The subcellular localization of the different PDEs
determines the functional compartmentalization of cAMP-
mediated responses. Inhibitory and stimulatory effects of
cAMP on cell proliferation have been linked with a cAMP
pool regulated by PDE3. In mesangial cells, PDE3 and PDE4
inhibitors increase cAMP levels and activate PKA to a similar
extent, but only PDE3 inhibitors block phosphorylation of
Raf-1 on serine 338 and suppress Raf-1 kinase activity and
extracellular signal-regulated kinase activation.50,51 PDE3,
but not PDE4 inhibitors, inhibit the proliferation of vascular
smooth muscle and endothelial cells.52 Conversely, only
PDE3 inhibitors suppress the proliferation of renal tubular
epithelial cells after the administration of folic acid, despite
the fact that PDE4 is three times more active than PDE3 in
suspensions of renal cortical tubules.53 PDE4 inhibitors are
more effective than PDE3 inhibitors in elevating intracellular
cAMP levels in MDCK cells, but only PDE3 inhibitors
stimulate MDCK cell proliferation.54
The proliferative response of the cystic epithelium to
cAMP can be completely abrogated by a PKA inhibitor. Other
cAMP effectors, such as exchanging protein directly activated
by cAMP and cAMP-gated ion channels, do not have a
significant role in the renal cystic epithelium, although
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Figure 6 |Cyclic AMP-dependent protein kinase A regulatory
and catalytic subunits in cystic and wild-type kidneys.
(a) cAMP-dependent protein kinase (PKA) regulatory- and
catalytic-subunit mRNA expression measured by reverse
transcriptase PCR (RT-PCR) in the kidneys of 10-week-old male
polycystic kidney (PCK; n¼ 6) and wild-type (n¼ 6) rats. (b) PKA
regulatory- and catalytic-subunit mRNA expression measured by
RT-PCR in the kidneys of 16-week-old male Pkd2/WS25 (n¼ 6) and
wild-type (n¼ 6) mice. (c) Western blots of PKA regulatory and
catalytic subunits in the kidneys of 10-week-old male PCK (n¼ 4)
and wild-type (n¼ 4) rats. (d) Western blots of PKA regulatory and
catalytic subunits in the kidneys of 16-week-old male Pkd2/WS25
(n¼ 4) and wild-type (n¼ 4) mice.
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exchanging protein directly activated by cAMP-specific
stimulation may contribute to the proliferation of the biliary
epithelium in polycystic liver disease.55 PKA is a tetrameric
holoenzyme with two R subunits and two C subunits.56–59
There are two major forms of PKA, PKA-I, and PKA-II,
determined by their different R-subunits (RI and RII). R-sub-
units are classified into a- and b-forms, resulting in four
distinct R-subunits, RIa, RIb, RIIa, and RIIb, encoded by
separate genes. Three C subunit isoforms have been described
(Ca, Cb, and Cg). In addition, a human X chromosome-
encoded protein kinase X60–62 and its rodent homolog
PKare63 have been identified as a novel C-subunit of PKA-I.
Binding of two cAMP molecules to each R-subunit releases the
C-subunits that are then able to phosphorylate target proteins.
PKA R subunits have different patterns of expression and
biological functions. RIa and RIIa are ubiquitously
expressed. RIb is expressed in neuronal tissues. RIIb is
expressed in brain, adipose, and some endocrine tissues. RI
subunits are more readily dissociated by cAMP, are involved
in the transition from G1 to S phase of the cell cycle and the
control of cell proliferation,63–65 and are overexpressed in
cancer cell lines.66,67 Early embryonic lethality of RIa-null
mice68 and lack of a severe phenotype of RIIa, RIIb, and RIb-
null mice point to the importance of the RIa in maintaining
the catalytic subunit under cAMP control.56 Heterozygous
Prkar1a mice develop tumors arising from cAMP-responsive
cells, such as Schwann, adrenal, and thyroid cells,69,70 and
tissue-specific ablation of Prkar1a from cranial neural crest
cells, pituitary cells, and cardiac myocytes leads to develop-
ment of schwannomas, pituitary adenomas,71 and cardiac
myxomas.72
Very few studies have focused on the expression of various
PKA subunits in polycystic kidneys. Higher expression of
RIIa and Ca have been described in epithelial cells cultured
Figure 7 | Immunolocalization of PKA regulatory subunits in cystic and wild-type kidneys. Immunolocalization of cAMP-dependent
protein kinase (PKA) RIa (a, d, g, j), RIIa (b, e, h, k), and RIIb (c, f, i, l) in wild-type rat (a–f, original magnification  200) and mouse
(g–i,  400) and in polycystic kidney (PCK) rat (j–l, original magnification  200) kidneys. The immunostaining pattern in Pkd2WS25/ mouse
(not shown) was similar to that of PCK rat kidneys.
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from cpk mouse cystic kidneys compared with wild-type
kidneys.73 Human X chromosome-encoded protein kinase, a
novel C subunit of PKA-I, is overexpressed in ADPKD
kidneys and has been reported to interact with PC1.60–62 Our
results show upregulation of RIa mRNA expression in cystic
kidneys of rats and mice, although at a protein level RIa
expression was increased only in the kidneys of Pkd2/WS25
mice. Ca, Cb, and PKare (the rodent homolog of human X
chromosome-encoded protein kinase) mRNA were also
overexpressed in cystic kidneys.
Cyclic AMP effects on cell proliferation may be due, at
least in part, to PKA-mediated phosphorylation of transcrip-
tion factors that bind to CREs in the regulatory region of
numerous genes.74,75 These include CREB, CREMs, and
ATF-1. The increased expression of CREB-1 mRNA in cystic
tissues and the significant elevations of CREM-1, ATF-1, and
ICER proteins in the nuclear extracts of cystic compared with
wild-type animals in this study is consistent with enhanced
PKA activity.
In summary, the results of this study suggest that
alterations in cyclic nucleotide catabolism may render the
cystic epithelium particularly susceptible to factors acting on
Gs-coupled receptors, account at least in part for the
upregulation of cyclic nucleotide signaling in PKD, and
contribute substantially to the progression of this disease.
MATERIALS AND METHODS
Tissue samples
Tissue samples from PCK and wild-type rats and from Pkd2WS25/
and wild-type mice and Pkd2WS25/WS25 mice were obtained as part of
previously published studies.13,14,20,21 At the time of killing, the left
kidney was removed under ketamine and xylazine anesthesia,
immediately frozen in liquid nitrogen, and ground to fine powder
under liquid nitrogen in a stainless steel mortar for determination of
cyclic nucleotides and for PCR and western analysis.
Cell lines
MDCKZeo and MDCKPKD1Zeo cell lines have been previously
described.28 The MDCKZeo cell line was derived by transfection
with pCIZeo of a parental MDCK that has no detectable PC1
expression by western blot analysis. The MDCKPKD1Zeo cell line
was derived from the same parental MDCK cell line and stably
expresses full-length human PKD1 cDNA.
PDE activity assay
Kidneys were homogenized in ice-cold homogenization buffer
containing 50 mM Tris pH 7.5, 0.25 M sucrose, 5 mM MgCl2, 1 mM
ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol
tetraacetic acid (EGTA), and 1 mM DTT, and supplemented with
protease inhibitor tablets (Roche, Mannheim, Germany). PDE
activities were measured using 1 mM cAMP as substrate in buffer
containing 50 mM Tris (pH 7.5), 5 mM MgCl2, 4 mM 2-mercap-
toethanol and 0.1% bovine serum albumin.76 3H-cAMP was
included as a tracer for quantitation. Assays were initiated by the
addition of substrate and incubated for 10 min at 30 1C. The
reaction was stopped by incubation for 3 min in boiling water.
Crotalus atrox snake venom was then added and after 15-min
incubation at 30 1C, hydrolyzed nucleotide was separated using
high-capacity pre-activated ion exchange resin (FabGennix, Frisco,
TX, USA). Slurries were mixed thoroughly and left to stand for
15 min on ice before centrifugation at 12,000 g for 3 min. The
radioactivity in 150ml aliquots of the resulting supernatants was
determined using liquid scintillation counting. To determine the
activity in a sample due to a specific PDE, various activators or
inhibitors were included in the assay. The PDE activity in aliquots
incubated without calcium was determined as a basal activity.
Calmodulin-stimulated PDE1 activity was determined by subtract-
ing the basal activity from the activity in the presence of 2.01 mM
CaCl2 and 10 mg/ml calmodulin. PDE3 and PDE4 activities were
determined as cAMP–PDE inhibitable by 10 mM cilostamide or
rolipram, respectively. Hydrolysis of cAMP was linearly proportional
with incubation time and enzyme protein. Specific activities were
defined as pmoles of cAMP hydrolyzed/min per mg protein.
Quantitative immunoblotting and Immunohistochemistry
Whole-tissue lysates were heated in a sample buffer, electrophoresed
on SDS-polyacrylamide gel, and transferred to polyvinylidene
fluoride membrane. After blocking at room temperature for 1 h
and incubating with primary antibody overnight at 4 1C, mem-
branes were washed and incubated with secondary antibody for 1 h
at room temperature. Detection was performed using enhanced
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Figure 8 |Cyclic AMP response element (CRE)-binding
transcription factors in cystic and wild-type kidneys. (a) CREB-1,
CREM-1, and ICER mRNA expression measured by reverse
transcriptase PCR (RT-PCR) in the kidneys of 10-week-old male
polycystic kidney (PCK; n¼ 6) rats and wild-type (n¼ 6) rats.
(b) CREB-1, CREM-1, and ICER mRNA expression measured by
RT-PCR in the kidneys of 16-week-old male Pkd2/WS25 (n¼ 6) and
wild-type (n¼ 6) mice. (c) Western blots of CREB, P-CREB, CREM-1,
ATF-1, and ICER in the kidneys of 10-week-old male PCK (n¼ 4)
rats and wild-type (n¼ 4) rats. (d) Western blots of CREB, P-CREB,
CREM-1, ATF-1, and ICER in the kidneys of 16-week-old male
Pkd2/WS25 (n¼ 4) and wild-type (n¼ 4) mice. ATF, activating
transcription factor; CREB-1, CRE-binding protein 1; CREM-1, CRE
modulator protein 1; ICER, inducible cAMP early repressor.
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chemiluminescence (Pierce Chemical, Rock Grove, IL, USA).
Paraffin-embedded tissue sections, 4 mm transverse, including
cortex, medulla, and papilla, were used for immunohistochemical
staining as described.14 PDE antibodies used were PDE1A (ab14599,
Abcam, Cambridge, MA, USA), PDE1C (ab14602, Abcam), PDE3A
(sc20792, Santa Cruz, CA, USA), PDE3B (sc20793, Santa Cruz),
PDE4A (ab14607, Abcam), PDE4B(ab14611, Abcam), and PDE4-
D(ab14613, Abcam). PKA antibodies used were PKARIa (610609,
BD Biosciences, San Jose, CA, USA); PKARIIa (612242, BD
Biosciences), PKARIIb (610625, BD Biosciences), and PKAC
(610980, BD Biosciences). CREB and phospho-CREB were pur-
chased from Cell Signaling (9190, Cell Signaling, Beverly, MA, USA).
CREB, ICER, and ATF-1 were detected by polyclonal antibody
CREM-1(sc440, Santa Cruz). PC1 was detected with the monoclonal
antibody 7e12.
Real-time polymerase chain reaction
PDE isoforms, PKA R and C subunits, CREB-1, CREM-1, and ICER
mRNAs were quantified using real-time PCR. Total RNA was
extracted from kidneys using an RNeasy plus mini kit (Qiagen,
Valencia, CA, USA). First-strand cDNA synthesis was performed
using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA).
Accumulation of PCR products was measured in real time by using
SYBR Green ER qPCR Supermix Universal Kit (Invitrogen). The
sequences of primers are listed in Supplementary Table 1. Reaction
was performed in ABI7900 (Applied Biosystems, Foster City, CA,
USA), starting with 10 min of preincubation at 95 1C followed by 40
amplification cycles. 18S was used as housekeeping gene for
arbitrary unit calculation for every tested gene. All PCR products
were confirmed using sequencing.
Cyclic AMP and GMP content of whole kidneys
Tissues were homogenized in 10 volumes of cold 5% trichloroacetic
acid in a glass-Teflon tissue grinder. After centrifugation at 600 g for
10 min, the supernatants were extracted with three volumes of
water-saturated ether. After drying the aqueous extracts, reconsti-
tuted samples were processed without acetylation using enzyme
immunoassay kits (Sigma-Aldrich, St Louis, MO, USA). The results
were expressed as pmol/mg of protein.
Three-dimensional culture in collagen gel
Cell lines were maintained as monolayer cultures in medium
containing a 1:1 mixture of Dulbecco’s modified Eagle’s medium/
Ham’s F12 nutrient medium containing 10% (vol/vol) fetal bovine
serum (Invitrogen). After trypsinization and removal of trypsin,
4000 MDCKPKD1Zeo cells or 2000 MDCKZeo cells were suspended
in ice-cold minimum essential medium containing 2.9 mg/ml
collagen type I (BD Biosciences), 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 27 mM NaHCO3, and
deposited in 24-well plates (0.4 ml per well). The temperature was
raised to 37 1C to cause gelation and trapping of the cells within the
matrix that attaches to the bottom of the well. Dulbecco’s modified
Eagle’s medium/Ham’s F12 nutrient medium (1.5 ml) supplemented
with 5% fetal bovine serum, 100 U/ml penicillin G, and 0.1 mg/ml
streptomycin was added above the gelled medium. The plates were
kept in a cell incubator in a humidified atmosphere of 5% carbon
dioxide in room air at 37 1C. The medium was replaced three times a
week and the cells are inspected using light microscopy and
photographed at regular intervals. The number and diameters of the
cysts in each well were measured using MetaMorph software
(Universal Imaging, West Chester, PA, USA). Results were expressed
as absolute number of cysts and average cyst volumes.
Statistical methods
Data were expressed as means±s.d. Comparisons between the
groups were performed using t-test.
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